Clinical Trial Update: Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

View source ↗

Summary

The expanded access program for Palopegteriparatide in hypoparathyroidism has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• Palopegteriparatide (palopegteriparatide)

Snippet

Sponsor: Ascendis Pharma Bone Diseases A/S | Conditions: Hypoparathyroidism | Status: APPROVED_FOR_MARKETING